GlaxoSmithKline plc (GSK) Analysts See $0.64 EPS

January 20, 2018 - By Maria Brooks

 GlaxoSmithKline plc (GSK) Analysts See $0.64 EPS

Analysts expect GlaxoSmithKline plc (NYSE:GSK) to report $0.64 EPS on February, 14.They anticipate $0.01 EPS change or 1.54 % from last quarter’s $0.65 EPS. GSK’s profit would be $1.45B giving it 14.92 P/E if the $0.64 EPS is correct. After having $0.85 EPS previously, GlaxoSmithKline plc’s analysts see -24.71 % EPS growth. The stock increased 0.08% or $0.03 during the last trading session, reaching $38.2. About 3.48 million shares traded. GlaxoSmithKline plc (NYSE:GSK) has risen 4.26% since January 20, 2017 and is uptrending. It has underperformed by 12.44% the S&P500.

GlaxoSmithKline plc (NYSE:GSK) Ratings Coverage

Among 18 analysts covering GlaxoSmithKline (NYSE:GSK), 8 have Buy rating, 1 Sell and 9 Hold. Therefore 44% are positive. GlaxoSmithKline had 27 analyst reports since September 8, 2015 according to SRatingsIntel. The rating was downgraded by Bank of America to “Hold” on Thursday, October 26. On Monday, December 7 the stock rating was maintained by Argus Research with “Buy”. The firm earned “Neutral” rating on Tuesday, October 20 by Credit Suisse. Cowen & Co maintained GlaxoSmithKline plc (NYSE:GSK) on Monday, December 11 with “Hold” rating. The rating was upgraded by BNP Paribas to “Neutral” on Wednesday, April 5. The stock has “Buy” rating by Bank of America on Wednesday, December 9. The firm has “Underweight” rating given on Friday, September 8 by Morgan Stanley. The rating was downgraded by Citigroup to “Neutral” on Wednesday, July 5. Bryan Garnier & Cie upgraded GlaxoSmithKline plc (NYSE:GSK) on Wednesday, January 27 to “Buy” rating. The stock of GlaxoSmithKline plc (NYSE:GSK) earned “Neutral” rating by BNP Paribas on Tuesday, September 15.

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company has market cap of $86.58 billion. It operates through four divisions: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. It has a 29.29 P/E ratio. The firm offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV.

More recent GlaxoSmithKline plc (NYSE:GSK) news were published by: Benzinga.com which released: “As Price Falls, Vetr Upgrades GlaxoSmithKline To Buy” on April 20, 2017. Also Marketwatch.com published the news titled: “GlaxoSmithKline PLC ADR” on May 21, 2009. Benzinga.com‘s news article titled: “GlaxoSmithKline Recent Pullback Delivers A Healthy Opportunity To Buy” with publication date: August 30, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: